Home / Pharmaceutical company intelligence
Maple Pharmaceuticals (Pvt.) Ltd. logo
Pharmaceutical company intelligence

Maple Pharmaceuticals (Pvt.) Ltd.

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi pharmaceutical manufacturer focused on prescription, generic and OTC medicines across multiple dosage forms.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date19 Aug 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Private pharmaceutical manufacturer
Address
Plot No. 147, Sector 23, Korangi Industrial Area, Karachi 74900, Pakistan · 74900
Phone
+92 21 35113931; +92 21 35113935; +92 21 35113937
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000620 Maple Pharmaceuticals (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000620 67 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx69public portfolio records represented
REG60unique registrations represented
IDX67indexed MedInfoBase presentations
SRC2additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR65current validated price records
G31generic molecules in indexed catalogue
DF3dosage-form groups
TA8therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMaple Pharmaceuticals (Pvt.) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maple-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026Anti-infectives27 · 40%Cardiovascular19 · 28%Hematology & thrombosis8 · 12%Gastrointestinal & hepatology4 · 6%Endocrine & metabolic3 · 4%CNS & mental health3 · 4%Vitamins, minerals & nutrition2 · 3%Other therapeutic areas1 · 1%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMaple Pharmaceuticals (Pvt.) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maple-pharmaceuticals-pvt-ltdGenerated 23 Sep 202667presentationsTablet60 · 90%Capsule4 · 6%Suspension3 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMaple Pharmaceuticals (Pvt.) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maple-pharmaceuticals-pvt-ltdGenerated 23 Sep 202663comparable productsBelow peer median16 · 25%Near peer median19 · 30%Above peer median28 · 44%Company median price position+4.2%Lowest-price equivalents4Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMaple Pharmaceuticals (Pvt.) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/maple-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,24 shared77% overlapGenome Pharmaceuticals (Pvt.) Ltd.23 shared74% overlapCCL Pharmaceuticals (Pvt.) Limited22 shared71% overlapBarrett Hodgson Pakistan (Pvt.) Ltd20 shared65% overlapTABROS PHARMA (PVT). LTD.20 shared65% overlapGlitz Pharma20 shared65% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives27 products · 40%
Cardiovascular19 products · 28%
Hematology & thrombosis8 products · 12%
Gastrointestinal & hepatology4 products · 6%
Endocrine & metabolic3 products · 4%
CNS & mental health3 products · 4%
Vitamins, minerals & nutrition2 products · 3%
Reproductive & genitourinary1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials8 products · 12%
Antiplatelet medicines8 products · 12%
Antimalarials7 products · 10%
Macrolide antibacterials6 products · 9%
Beta blockers5 products · 7%
Diuretics4 products · 6%
Nitrates / antianginals4 products · 6%
Angiotensin II receptor blockers4 products · 6%
Formulation footprint

Dosage forms

Tablet60 products
Capsule4 products
Suspension3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CIPROZEECiprofloxacin 4presentations 1000 mg, 250 mg, 500 mg, 750 mg · Tablet #2 LOSAANLosartan 4presentations 25 mg, 50 mg · Tablet #3 MOSQINETArtemether + Lumefantrine 4presentations 20 mg + 120 mg, 40 mg + 240 mg, 80 mg + 480 mg · Tablet #4 BISMAPBisoprolol fumarate 3presentations 10 mg, 2.5 mg, 5 mg · Tablet #5 LEVOLIFELevofloxacin 3presentations 250 mg, 500 mg, 750 mg · Tablet #6 LOCLOGClopidogrel 3presentations 75 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1625% of comparable products
Near market median19within ±5% of median
Above market median2844% of comparable products
Lowest-price equivalents4ties included
Company median price position +4.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
CEFIXOMAP 100 mg/5 mLCefixime · Suspension · 60ML PKR 4.41/mL-57.9% vs market median LACTONAR 25 mgSpironolactone · Tablet · 10x10's PKR 2.30/tablet-53.8% vs market median METMIN 250 mgMetformin · Tablet · 6x10's PKR 1.59/tablet-32.3% vs market median MAPZIT 250 mgAzithromycin · Capsule · 10's PKR 38.27/capsule-22.7% vs market median MAPZIT 250 mgAzithromycin · Capsule · 6's PKR 38.27/capsule-22.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 24shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 23shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 22shared generics Barrett Hodgson Pakistan (Pvt.) Ltd187 products · 63 generics 20shared generics TABROS PHARMA (PVT). LTD.179 products · 65 generics 20shared generics Glitz Pharma170 products · 73 generics 20shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers58Distinct registrations among indexed, published, presentation-validated products only
Verified price observations123
Products with a verified price67
Products with multiple price observations56
Source records with multiple versions66
Latest portfolio source check22 Sep 2026
Latest effective price date19 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

60 unique registration(s) · 67 indexed presentation(s) · 2 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
ASUMIDE Furosemide 20 mg Tablet 10x10's 089030 PKR 230.53 PKR 2.31/tablet 17% above median
ASUMIDE Furosemide 40 mg Tablet 10x10's 089031 PKR 365.33 PKR 3.65/tablet 6% above median
BISMAP Bisoprolol fumarate 2.5 mg Tablet 2x7's 089027 PKR 63.11 PKR 4.51/tablet 7% above median
BISMAP Bisoprolol fumarate 5 mg Tablet 2x10's 089028 PKR 242.69 PKR 12.13/tablet Near median
BISMAP Bisoprolol fumarate 10 mg Tablet 2x10's 089029 PKR 445.97 PKR 22.30/tablet Near median
CEFIXOMAP Cefixime 100 mg/5 mL Suspension 60ML 118024 PKR 264.86 PKR 4.41/mL 58% below median
CHLORIXNE Hydroxychloroquine 200 mg Tablet 5x10's 105438 PKR 643.52 PKR 12.87/tablet 11% below median
CHLORIXNE Hydroxychloroquine 200 mg Tablet 3x10's 105438 PKR 386.11 PKR 12.87/tablet 11% below median
CIPROZEE Ciprofloxacin 250 mg Tablet 10's 070687 PKR 263.01 PKR 26.30/tablet Near median
CIPROZEE Ciprofloxacin 500 mg Tablet 10's 070688 PKR 434.98 PKR 43.50/tablet Near median
CIPROZEE Ciprofloxacin 750 mg Tablet 10's 076113 PKR 480.53 PKR 48.05/tablet 21% above median
CIPROZEE Ciprofloxacin 1000 mg Tablet 10's 083698 PKR 751.84 PKR 75.18/tablet No comparator
Citricko Ascorbic acid 500 mg Chewable tablet 4x10's 107441 PKR 45.02 PKR 1.13/tablet 15% below median
CO-VALSETA 160Source observed Amlodipine 12.5 mg Tablet 2x7's 067531Official source ↗ No indexed price — —
CO-VALSETA 80Source observed Amlodipine 12.5 mg Tablet 2x7's 083349Official source ↗ No indexed price — —
CURASOFT-EFF Ranitidine 150 mg Effervescent tablet 10's 053158 PKR 151.74 PKR 15.17/tablet No comparator
CURASOFT-EFF Ranitidine 300 mg Tablet 10's 053159 PKR 313.39 PKR 31.34/tablet 54% above median
CVPRIN Acetylsalicylic acid (Aspirin) 75 mg Tablet 3x10's 036671 PKR 68.00 PKR 2.27/tablet 18% above median
CVPRIN Acetylsalicylic acid (Aspirin) 150 mg Tablet 3x10's 036672 PKR 85.84 PKR 2.86/tablet 17% above median
GLYRATE-SR Nitroglycerin 2.6 mg Sustained-release tablet 3x10's 055421 PKR 329.86 PKR 11.00/tablet 26% above median
GLYRATE-SR Nitroglycerin 6.4 mg Sustained-release tablet 3x10's 055422 PKR 388.70 PKR 12.96/tablet Near median
ISDIN Isosorbide dinitrate 10 mg Tablet 10x10's 017574 PKR 241.93 PKR 2.42/tablet 114% above median
ISDIN Isosorbide dinitrate 10 mg Tablet 100x10's 017574 PKR 1,935.52 PKR 1.94/tablet 71% above median
JEMZOX Metronidazole 200 mg/5 mL Suspension 60ml 061709 PKR 45.55 PKR 0.76/mL 18% below median
JEMZOX Metronidazole 400 mg Tablet 10x10's 061710 PKR 241.97 PKR 2.42/tablet 20% below median
LACTONAR Spironolactone 25 mg Tablet 10x10's 090935 PKR 229.53 PKR 2.30/tablet 54% below median
LACTONAR Spironolactone 100 mg Tablet 10's 090936 PKR 121.77 PKR 12.18/tablet 17% below median
LEVOLIFE Levofloxacin 250 mg Tablet 10's 048794 PKR 505.79 PKR 50.58/tablet 5% above median
LEVOLIFE Levofloxacin 500 mg Tablet 10's 048795 PKR 841.63 PKR 84.16/tablet 6% above median
LEVOLIFE Levofloxacin 750 mg Tablet 10's 048796 PKR 1,011.59 PKR 101.16/tablet 9% above median
LOCLOG Clopidogrel 75 mg Tablet 100x10's 034943 PKR 24,777.59 PKR 24.78/tablet 9% below median
LOCLOG Clopidogrel 75 mg Tablet 10's 034943 PKR 284.84 PKR 28.48/tablet Near median
LOCLOG Clopidogrel 75 mg Tablet 10×10's 034943 PKR 2,398.69 PKR 23.99/tablet 12% below median
LOCLOG Clopidogrel + Aspirin 75 mg + 75 mg Tablet 10's 053122 PKR 279.55 PKR 27.96/tablet Near median
LOCLOG-AP Clopidogrel + Aspirin 75 mg + 75 mg Tablet 10's 053122 PKR 279.55 PKR 27.96/tablet Near median
LOCLOG-AP Clopidogrel + Aspirin 75 mg + 150 mg Tablet 10's 053123 PKR 289.20 PKR 28.92/tablet Near median
LOSAAN Losartan + Hydrochlorothiazide 50 mg + 12.5 mg Tablet 2x10's 031713 PKR 1,186.76 PKR 59.34/tablet 92% above median
LOSAAN Losartan 50 mg Tablet 100x10's 031717 PKR 24,777.59 PKR 24.78/tablet 19% above median
LOSAAN Losartan 50 mg Tablet 2x10's 031717 PKR 609.31 PKR 30.47/tablet 47% above median
LOSAAN Losartan 50 mg Tablet 10x10's 031717 PKR 2,648.02 PKR 26.48/tablet 28% above median
LOSAAN Losartan 25 mg Tablet 2x10's 076112 PKR 231.12 PKR 11.56/tablet Near median
LYTRON FORTE Losartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 10's 061266 PKR 992.68 PKR 99.27/tablet No comparator
MAPFOLIC Folic acid 5 mg Tablet 10x10's 086878 PKR 95.65 PKR 0.96/tablet 20% above median
MAPNOLOL Propranolol 10 mg Tablet 5x10's 090937 PKR 94.09 PKR 1.88/tablet Near median
MAPNOLOL Propranolol 40 mg Tablet 5x10's 090938 PKR 194.84 PKR 3.90/tablet 21% above median
MAPZIT Azithromycin 500 mg Tablet 6's 105383 PKR 412.68 PKR 68.78/tablet 19% below median
MAPZIT Azithromycin 250 mg Capsule 6's 105384 PKR 229.61 PKR 38.27/capsule 23% below median
MAPZIT Azithromycin 250 mg Capsule 10's 105384 PKR 382.68 PKR 38.27/capsule 23% below median
MEFSUNATE Artesunate + Mefloquine 100 mg + 250 mg Tablet 3's+3's 076240 PKR 222.55 — No comparator
METMIN Metformin 250 mg Tablet 6x10's 066768 PKR 95.54 PKR 1.59/tablet 32% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Maple Pharmaceuticals (Pvt.) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/maple-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.